PRIMARY OBJECTIVES:
I. To obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE).
OUTLINE: Patients choose 1 of 2 groups.
GROUP I: Patients undergo IPC placement and receive doxycycline via IPC 5 days later.
GROUP II: Patients undergo IPC placement.
After completion of study treatment, patients are followed up at 10-14 days and then monthly for up to a year.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatients with MPE undergoing IPC placement
Sufficient mental capacity to provide informed consent and answer Short-Form Six-Dimension health index (SF-6D) and Borg score questions
Inpatients that are expected to be discharged within 5 days of receiving an indwelling pleural catheter
You may not be if
Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)
Inability or unwillingness to give informed consent
Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)
Pregnancy
Previous intrapleural therapy for MPE on the same side
Eastern Cooperative Oncology Group (ECOG) of 4 and life expectancy =\< 2 weeks
Doxycycline allergy
Extensive loculations or hydropneumothorax or other contraindication to pleurodesis
Chylous effusions associated with malignant disease
Clareo Health | Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
